Lipocine Inc. Files 8-K: Other Events & Exhibits
Ticker: LPCN · Form: 8-K · Filed: Nov 18, 2024 · CIK: 1535955
| Field | Detail |
|---|---|
| Company | Lipocine Inc. (LPCN) |
| Form Type | 8-K |
| Filed Date | Nov 18, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, disclosure
TL;DR
Lipocine filed an 8-K on Nov 18, 2024, for other events and exhibits. No specific details yet.
AI Summary
Lipocine Inc. filed an 8-K on November 18, 2024, reporting other events and financial statements. The company, previously known as Marathon Bar Corp until November 30, 2011, is incorporated in Delaware and headquartered in Salt Lake City, Utah. The filing does not detail specific transactions or financial figures but serves as a notification of events and exhibit filings.
Why It Matters
This filing indicates Lipocine Inc. is providing updates or submitting required documentation to the SEC, which could contain material information for investors.
Risk Assessment
Risk Level: low — The filing is a routine disclosure and does not contain specific negative or positive news that would immediately impact risk.
Key Players & Entities
- Lipocine Inc. (company) — Registrant
- Marathon Bar Corp (company) — Former company name
- November 18, 2024 (date) — Date of report
- November 30, 2011 (date) — Date of former company name change
- 675 Arapeen Drive, Suite 202 (address) — Principal executive offices
- Salt Lake City, Utah 84108 (address) — Principal executive offices
- 001-36357 (other) — Commission File Number
FAQ
What specific 'Other Events' are being reported by Lipocine Inc. in this 8-K filing?
The provided text does not specify the 'Other Events' being reported, only that this section is included in the filing.
What financial statements or exhibits are being filed by Lipocine Inc. on November 18, 2024?
The filing indicates that 'Financial Statements and Exhibits' are part of the report, but the specific contents are not detailed in the provided text.
When did Lipocine Inc. change its name from Marathon Bar Corp?
Lipocine Inc. changed its name from Marathon Bar Corp on November 30, 2011.
What is the principal executive office address for Lipocine Inc.?
The principal executive offices of Lipocine Inc. are located at 675 Arapeen Drive, Suite 202, Salt Lake City, Utah 84108.
What is the Commission File Number for Lipocine Inc.?
The Commission File Number for Lipocine Inc. is 001-36357.
Filing Stats: 442 words · 2 min read · ~1 pages · Grade level 11.3 · Accepted 2024-11-18 09:45:09
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share LPCN The NASDAQ Stock Mar
Filing Documents
- form8-k.htm (8-K) — 39KB
- ex99-1.htm (EX-99.1) — 22KB
- form8-k_001.jpg (GRAPHIC) — 6KB
- 0001493152-24-046444.txt ( ) — 253KB
- lpcn-20241118.xsd (EX-101.SCH) — 3KB
- lpcn-20241118_lab.xml (EX-101.LAB) — 33KB
- lpcn-20241118_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
01
Item 8.01 Other Events The Company issued a press release announcing the publication and discussion of LPCN 1148 Manuscript at The Liver Meeting (AASLD) 2024 Editor's Cut Session which was held on November 16, 2024. The press release is filed as Exhibits 99.1. Item 9.01 Financial (d) Exhibits The following exhibits are filed with this report: Exhibit No. Description 99.1 Press Release announcing Publication and Discussion of LPCN 1148 Manuscript at the Liver Meeting 2024 Editor's Cut Session 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LIPOCINE INC. Date: November 18, 2024 By: /s/ Mahesh V. Patel Mahesh V. Patel President and Chief Executive Officer